Cibus, Inc. announced that two of its disease resistance trait products under development for canola have been designated as not regulated by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS) Biotechnology Regulatory Services (BRS). This designation confirms the plants do not meet the definition of a 'regulated article' under 7 CFR Part 340.
This regulatory decision allows Cibus to proceed with product development without restrictions associated with regulated articles in the U.S. Peter Beetham, Interim CEO, stated that this broad designation is encouraging and supports the promise of gene-editing technologies.
The Sclerotinia resistance trait in canola, which offers multiple modes of action, is expected to help farmers improve yields and lower input costs by reducing reliance on fungicides. Greg Gocal, Chief Scientific Officer, noted that the application of these traits is expected to extend to other crops like soybean, expanding benefits to additional acres and geographies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.